Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.

被引：106

作者：

Fakih, Marwan

O'Neil, Bert

Price, Timothy Jay

Falchook, Gerald Steven

Desai, Jayesh

Kuo, James

Govindan, Ramaswamy

Rasmussen, Erik

Morrow, Phuong Khanh H.

Ngang, Jude

Henary, Haby A.

Hong, David S.

机构：

[1] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Clin Res, Duarte, CA USA

[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[3] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA, Australia

[4] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Scientia Clin Res, Randwick, NSW, Australia

[7] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.3003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3003

引用

页数：1